Core Biogenesis, a topical delivery platform for active proteins, grown in seeds.

Name: Peauvita
Brand: Core Biogenesis

The oleosome fusion platform fuses active peptides and proteins of interest to oleosin, the natural anchor of camelina lipid droplets, and grows them inside camelina seeds. What emerges is a self-stabilising carrier that delivers biomimetic proteins deeper into skin and scalp, formulation-ready.

The platform: one platform, two engines, any active protein.

Core Biogenesis runs a dual bioproduction and delivery platform built on oleosome fusion in camelina seeds. The recombinant protein is fused to oleosin and grown displayed on the surface of the seed's oleosome, the very same droplet that then carries it intact onto skin and scalp. One molecule designed once, grown and delivered by the same biology.

Engine 01: bioproduction in seeds.

Recombinant proteins are produced natively in camelina seeds, fused to oleosin on the surface of each oleosome. No fermenter, no animal cells. Surface-displayed expression on camelina oleosomes. No fermentation infrastructure, maximal plant scalability. Zero animal-derived components, GMO-free products.

Engine 02: delivery via oleosomes.

The same oleosome that produced the protein doubles as its carrier. The active stays anchored to a native lipid droplet, biomimetic to the skin barrier. Protein displayed on a lipid carrier the skin recognises. Room-temperature stable, 12-month ambient shelf life. Penetrates skin and scalp; drops into any formulation.

Protein versatility

15+ proteins to date across multiple functional classes, from kilo-Daltons to peptides: growth factors (EGF, FGF, KGF), antioxidant enzymes (superoxide dismutase, catalase), antimicrobials (lactoferrin, defensins), biomimetic peptides, structural proteins, and endolysin enzymes (anti-C. acnes, anti-S. aureus).

The pipeline: three actives on the market, six more in development.

Our launched products are commercially available and formulator-ready today. The development pipeline reflects the platform's ability to express and stabilize a broad spectrum of recombinant proteins for skin and scalp applications.

Launched: peauvita (EGF-oleosome fusion)

Oleosome-delivered EGF for epidermal rejuvenation. Stimulates epidermal cell renewal, accelerates post-procedure recovery, improves skin barrier function, reduces the appearance of fine lines.

Launched: peauforia (FGF-2-oleosome fusion)

Oleosome-delivered FGF-2 for dermal renewal. Boosts fibroblast activity and collagen synthesis, restores firmness and elasticity, smooths wrinkle depth, supports dermal remodeling.

Launched: peaureva (FGF-2-oleosome fusion hair formula)

Oleosome-delivered FGF-2 for follicle vitality. Stimulates dermal papilla cells, prolongs anagen phase, improves hair density and thickness, supports follicle vitality.

In development

Lactoferrin (clinical, partnered), superoxide dismutase, KGF, IGF-1, albumin, and endolysin enzymes are in development across discovery, expression, preclinical and clinical stages.

Studies: four clinical studies, measurable results.

Every Core Biogenesis active is validated in independent, placebo-controlled or head-to-head clinical trials, conducted by ISO-certified CROs and supervised by dermatologists. Each result is statistically significant and instrumentally measured.

Head-to-head: 1% Peauvita (EGF-oleosome fusion) plus 1% Peauforia (FGF-2-oleosome fusion) versus 0.3% retinol. At day 30: minus 25.5% wrinkle depth, minus 27.2% wrinkle length, 77% of users with visibly smoother skin, significantly brighter skin. Conducted by AbiCh Lifeanalytics, published in SOFW Journal, November 2025.

Peauvita at 28 days: plus 21.8% skin firmness at day 14, minus 7.5% wrinkles at day 28, both significantly better than placebo.

Peauforia at 14 days: minus 14.8% melanin in hyperpigmentation zones, plus 15.5% skin barrier restoration (TEWL).

Peaureva at 28 days: plus 33.6% hair density, plus 14.0% anagen/telogen ratio, plus 5.0% shaft thickness, plus 17.5% scalp hydration. Durability confirmed through day 84.

About Core Biogenesis

Core Biogenesis was founded in 2020 in Paris, France by Alexandre Reeber and Chouaib Meziadi. A French biotech reinventing how the cosmetics and personal care industry uses active proteins. 20+ scientists, engineers, and operators across Paris and Strasbourg.

Recognition: C&T Allē Award 2026, EcoVadis Platinum 2026 (top 1% of companies worldwide for sustainability), L'Oréal Big Bang Beauty Tech Innovation Challenge winner 2025.

Certifications: EcoVadis Platinum, COSMOS-approved, vegan-suitable, cruelty-free, non-GMO products (iGen certification), endotoxin-free.

Insights: scientific content library

A scientific content library on growth factors, oleosomes, biotech skincare actives, formulation, and clinical evidence. Written for formulators, R&D teams, and brand leaders evaluating the next generation of topical actives.

Contact

Talk to the platform team. Request samples, formulation data, or clinical reports. The contact form on the live page sends submissions to the Core Biogenesis platform team in France.